 |
|
Tumors stopped from spreading to new sites
April 06, 2007For several types of cancer, persistently high levels of the soluble factor TGF-beta in the blood after surgery, chemotherapy, or radiation therapy correlate with increased risk of early metastasis and a poor prognosis. Using a mouse model of breast cancer, researchers from Vanderbilt University have now generated evidence to suggest that treatment with TGF-beta inhibitors might help such patients.
In the study, which appears online on April 5 in advance of publication in the May print issue of the Journal of Clinical Investigation, Carlos Arteaga and colleagues show that treating mice with mammary tumors with either radiation or the chemotherapeutic drug doxorubicin increased the level of TGF-beta in their blood, the number of cancer cells in their blood, and the development of lung metastases. Treatment with an inhibitor of TGF-beta blocked the increased lung metastases. Furthermore, mice whose tumors did not express the receptor for TGF-beta did not develop increased incidence of lung metastases after treatment with radiation, indicating that TGF-beta affects the cancer cells directly, enhancing their metastatic function. This study has important clinical implications as it suggests that monitoring TGF-beta levels after primary therapy might indicate the patients most at risk of developing tumor metastases and that treatment with TGF-beta inhibitors might be of clinical benefit to these individuals.
Journal of Clinical Investigation
Lung Metastases Current Events and Lung Metastases News RSSGene signature helps predict breast cancer prognosis
Vanderbilt-Ingram Cancer Center researchers have uncovered a gene signature that may help predict clinical outcomes in certain types of breast cancer.
miR-196a promotes the metastases of tumors
MicroRNAs are small RNA molecules of 20-25 nucleotides length, regulating gene expression by inhibition of transcription or translation of proteins.
Researchers identify potential therapeutic target in osteosarcoma
A receptor known to be active in bone metastases, but previously unexplored in primary bone tumors, is a potential therapeutic target in osteosarcoma, investigators from The University of Texas M. D. Anderson Cancer Center report in the March 1 issue of Cancer Research.
A genetic 'gang of 4' drives spread of breast cancer
Studies of human tumor cells implanted in mice have shown that the abnormal activation of four genes drives the spread of breast cancer to the lungs.
Curcumin halts spread of breast cancer in mice
Curcumin, the main ingredient of turmeric and the compound that gives curry its mustard-yellow color, inhibits metastasis to the lungs of mice with breast cancer.
Researchers identify gene set linked to breast cancer's spread to lungs
In a potential advance for the treatment of aggressive breast cancer, scientists at Memorial Sloan-Kettering Cancer Center (MSKCC) have identified a set of genes in breast tumors that appear to predict if the disease will spread to the lungs and, once there, how virulent it will become.
More Lung Metastases Current Events and Lung Metastases News Articles
|
Should we treat lung metastases from adenoid cystic carcinoma of the head and neck in asymptomatic patients?(ORIGINAL ARTICLE)(Report): An article from: Ear, Nose and Throat Journal by Irfan M. Syed (Author), David J. Howard (Author) This digital document is an article from Ear, Nose and Throat Journal, published by Vendome Group LLC on June 1, 2009. The length of the article is 3524 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: Should we treat lung metastases from adenoid cystic carcinoma of the head and neck in asymptomatic patients?(ORIGINAL ARTICLE)(Report) Author: Irfan M. Syed Publication: Ear, Nose and Throat Journal (Magazine/Journal) Date: June 1, 2009 Publisher: Vendome Group LLC Volume: 88 Issue: 6 Page: 969(5) Article Type: Report Distributed by Gale, a part of Cengage... | |
 |
Lung Metastases And Isolated Lung Perfusion by P. Van Schil (Editor) Surgical resection of lung metastases is a widely accepted procedure but long-term results are disappointing with a 5-year survival rate of approximately 40 per cent. The main prognostic factor is complete resection and a better survival is reported in patients with a single metastasis and a disease-free survival of more than 3 years. Re-operations are feasible but often patients become inoperable due to insufficient pulmonary reserve and new treatment modalities are looked for. Intravenous (iv) chemotherapy has no major impact on survival due to systemic side-effects when high doses are given. As isolated limb and liver perfusion, isolated lung perfusion (ILuP) has the advantage of selectively delivering an agent into the lung while diverting the venous effluent. This allows the drug to... |
|
Therapy of Lung Metastases (Contributions to Oncology, Vol 30) by P. Drings (Author), I. Vogt-Moykopf (Editor) | |
|
Analysis of the clonal composition of individual lung metastases and the stability of the metastatic phenotype: A dissertation in anatomy by James S Tzeng (Author) | |
 |
Frozen Section Library: Lung by Timothy Craig Allen (Author), Philip T. Cagle (Author) Frozen sections are performed for the purpose of rapid diagnosis while a patient is undergoing surgery, usually under general anesthesia, as a basis for making immediate treatment decisions. Therefore, frozen section diagnosis is often a highly demanding situation for the pathologist who must render a diagnosis quickly and a crucial determination for the patient and surgeon. In addition to the need for rapid recall of differential diagnoses, there are many pitfalls and artifacts that add to the risk of frozen section diagnosis that are not present with permanent sections of fully processed tissues that can be examined in a more leisurely fashion. Most standard pathology textbooks, both general and subspecialty, largely ignore the topic of frozen section. Few textbooks have ever focused... |
|
Bone metastases in lung cancer: A clinical study in 200 consecutive patients with bronchogenic carcinoma and its therapeutic implications for small cell carcinoma by Heine Høi Hansen (Author) | |
 |
Minimally Invasive Tumor Therapies (Recent Results in Cancer Research) by C. Stroszczynski (Editor) In the age of the World Wide Web, informed patients continue to surprise oncologists with detailed questions about popular tumor therapies. Although Minimally Invasive Tumor Therapies (MITT) have become daily clinical practice for palliative treatment of liver tumors, the acceptance of these palliative modalities still varies enormously. In addition, promising results have been published for in situ ablation of lung metastases, bone tumors, and renal cell carcinoma. This book gives an up-to-date overview of the popular techniques and clinical results of MITT, with a clarification of the actual indications, including the size, tumor entities, and clinical benefits. Moreover, the book focuses on the prospectives and limitations of imaging methods - ultrasound, computed tomography, and... |
|
Bronchogenic carcinoma;: A follow-up study of a surgically treated series with special reference to the prognostic significance of lymph node metastases, (Acta chirurgica Scandinavica) by Nils P Bergh (Author) |
| © 2009 BrightSurf.com |